An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Gilead Sciences (NASDAQ:GILD) stock fell 2.8% Monday morning following reports that Health and Human Services Secretary Robert F. Kennedy Jr. plans to dismiss all members of a key advisory panel that ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Lenacapavir can prevent 100 percent of HIV infections after just two injections per year, but getting it to SA could be a ...

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.

After purging the CDC’s vaccine advisory committee and replacing it with his own appointments, U.S. Health Secretary Robert F ...

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...